


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:03Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405397" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405397</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Int Ophthalmol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>International Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0165-5701</issn><issn pub-type="epub">1573-2630</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405397</article-id><article-id pub-id-type="pmcid-ver">PMC12405397.1</article-id><article-id pub-id-type="pmcaid">12405397</article-id><article-id pub-id-type="pmcaiid">12405397</article-id><article-id pub-id-type="pmid">40892272</article-id><article-id pub-id-type="doi">10.1007/s10792-025-03738-5</article-id><article-id pub-id-type="publisher-id">3738</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Jueling Mingmu decoction combined with ranibizumab for retinal vein occlusion induced macular edema: A randomized controlled clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hongyan</surname><given-names initials="W">Wu</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yao</surname><given-names initials="Z">Zhou</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hangshuai</surname><given-names initials="Z">Zhou</given-names></name><address><email>350589935@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04fszpp16</institution-id><institution-id institution-id-type="GRID">grid.452237.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 9098</institution-id><institution>Department of Ophthalmology, </institution><institution>Dongyang People&#8217;s Hospital, </institution></institution-wrap>NO.60 Wu Ning Xi Road, Dongyang, Zhejiang China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>45</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">496088</issue-id><elocation-id>372</elocation-id><history><date date-type="received"><day>29</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="10792_2025_Article_3738.pdf"/><abstract id="Abs1"><sec><title>Background/aims</title><p id="Par1">To investigate the efficacy of a combined treatment approach using Jueling Mingmu Decoction and ranibizumab in managing macular edema (ME) associated with retinal vein occlusion (RVO).</p></sec><sec><title>Methods</title><p id="Par2">This prospective, randomized, controlled, outcome assessor&#8211;blinded superiority trial involved 111 patients with treatment-na&#239;ve RVO and ME, including 53 patients assigned to the ranibizumab monotherapy group and 58 to the combination therapy group. Participants were randomly assigned to receive either intravitreal injections of 0.5&#160;mg ranibizumab alone (monotherapy group) or combined with daily consumption of Jueling Mingmu Decoction (combination group). Primary outcomes included the number of intravitreal injections administered over 48&#160;weeks. Secondary outcomes included changes in best-corrected visual acuity (BCVA) and central subfield fovea thickness (CST).</p></sec><sec><title>Results</title><p id="Par3">99 patients (89.2%) completed the 48-week follow-up, including 46 of 53 patients (86.8%) in the monotherapy group and 53 of 58 patients (91.4%) in the combination group. The monotherapy group received an average of 4.35&#8201;&#177;&#8201;1.73 injections, while the combination group received 4.64&#8201;&#177;&#8201;1.92 injections (<italic toggle="yes">P</italic>&#8201;=&#8201;0.471), with no significant difference between the groups. BCVA improved significantly in both groups, with the combination group showing a greater improvement at 48&#160;weeks in patients with branch RVO (BRVO) compared to the monotherapy group (<italic toggle="yes">P</italic>&#8201;=&#8201;0.031). CST decreased significantly in both groups, with the combination group showing a significantly lower CST at 36&#160;weeks in BRVO patients (<italic toggle="yes">P</italic>&#8201;=&#8201;0.018). No significant differences were observed between the groups for central retinal vein occlusion (CRVO) patients.</p></sec><sec><title>Conclusion</title><p id="Par4">The combination of Jueling Mingmu Decoction and ranibizumab appears to be a potentially effective treatment for improving visual and anatomical outcomes in RVO-related ME, especially in BRVO patients. However, it does not significantly reduce the number of required intravitreal injections compared to monotherapy. Further studies are needed to confirm these findings and explore the long-term efficacy and safety of this treatment approach.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Retinal vein occlusion</kwd><kwd>Macular edema</kwd><kwd>Ranibizumab</kwd><kwd>Traditional Chinese Medicine</kwd></kwd-group><funding-group><award-group><funding-source><institution>Jinhua Traditional Chinese Medicine Science and Technology Research Program</institution></funding-source><award-id>2023KY34</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature B.V. 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">RVO, encompassing branch BRVO and central CRVO, is the second most common retinal vascular disorder [<xref ref-type="bibr" rid="CR1">1</xref>], with a reported global prevalence of 0.50% [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Macular edema is a frequent cause of vision loss associated with RVO [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Recently, treatment approaches for ME caused by RVO include anti-vascular endothelial growth factor (anti-VEGF) agents, corticosteroid therapies, and macular laser procedures [<xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par6">Anti-VEGF injections are widely regarded as the first-line treatment for RVO-related ME [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. However, there is a noticeable gap between the visual and anatomical outcomes achieved in clinical trials and those observed in real-world settings. Many patients undergoing routine anti-VEGF treatment do not experience the same degree of improvement as reported in trials [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Furthermore, the requirement for frequent injections places a considerable financial burden on patients [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par7">Studies investigating combined therapies, such as intravitreal ranibizumab injections paired with retinal laser treatment, have shown that this approach does not reduce the number of required injections or enhance visual outcomes [<xref ref-type="bibr" rid="CR14">14</xref>]. On the other hand, dexamethasone implants, known for their strong anti-inflammatory properties, effectively reduce macular edema and suppress neovascularization [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. However, their use is associated with significant risks, including elevated intraocular pressure, cataract development, and noninfectious endophthalmitis [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par8">While VEGF is recognized as a key factor in the development of ME in RVO, targeting VEGF alone may not fully address the condition. The RELATE study demonstrated that increasing ranibizumab anti-VEGF dosing did not lead to better clinical outcomes in RVO patients [<xref ref-type="bibr" rid="CR14">14</xref>]. This suggests that addressing additional disease pathways beyond VEGF could enhance treatment efficacy and long-term results.</p><p id="Par9">RVO is primarily linked to cardiovascular risk factors, especially in the elderly, which contribute to retinal neuronal damage and optic nerve impairment. According to Traditional Chinese Medicine (TCM), RVO-induced ME is associated with systemic dysfunction, classically described as imbalances in Yin and Yang and stagnation of Qi and blood in the retinal microcirculation. From a biomedical perspective, these descriptions can be interpreted as corresponding to microcirculatory impairment, local inflammatory responses, and fluid accumulation, all of which are implicated in RVO pathophysiology. Herbal formulations such as Jueling Mingmu Decoction have been traditionally used to &#8220;clear heat&#8221; and &#8220;promote diuresis,&#8221; which can be viewed as exerting anti-inflammatory effects, improving microcirculation, and reducing retinal vascular congestion. Previous pharmacological studies [<xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>] suggest that active components in its ingredients, including salvianolic acid B (from Salvia miltiorrhiza) and triterpenoids (from Poria), can reduce oxidative stress, improve collateral circulation, and enhance retinal microvascular perfusion, thereby potentially supporting edema resolution in RVO.</p><p id="Par10">Previous studies [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] have indicated that Chinese herbal medicines with properties that activate blood circulation and alleviate blood stasis may reduce retinal edema in RVO patients, potentially decreasing the frequency of anti-VEGF injections and improving vision. One such formulation, Jueling Mingmu Decoction, consists of lycopsia, cassia, wormwood, chrysanthemum, red peony, schizonepeta, poria, plantago, salvia miltiorrhiza, rice bud, and licorice. Known for its ability to clear liver heat, promote diuresis, activate blood circulation, and strengthen the stomach and spleen, this decoction offers a targeted approach to managing RVO-induced ME.</p><p id="Par11">This study aims to explore the efficacy of combining Jueling Mingmu Decoction with ranibizumab in treating ME associated with RVO through a randomized, outcome assessor&#8211;blinded trial.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par12">This prospective, randomized, controlled, outcome assessor&#8211;blinded trial was designed to evaluate the efficacy of combining Jueling Mingmu Decoction with ranibizumab for the treatment of macular edema associated with retinal vein occlusion. The study received approval from the Institutional Ethical Committee of Dongyang People's Hospital and adhered to the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from all participants prior to enrollment. This study was registered at ClinicalTrials.gov (Identifier: <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT06234514">NCT06234514</ext-link>) on January 30, 2024.</p><sec id="Sec3"><title>Patient eligibility and exclusion criteria</title><p id="Par13">Participants eligible for inclusion were aged 18&#160;years or older, diagnosed with treatment-na&#239;ve RVO within the past 9&#160;months, presented with a BCVA letter score of 73 to 24 on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart (Snellen equivalent: 20/40 to 20/320), and demonstrated a CST of 250&#160;&#956;m or greater on spectral-domain optical coherence tomography (SD-OCT) using Spectralis HRA&#8201;+&#8201;OCT (Heidelberg Engineering). The&#8201;&#8805;&#8201;250&#160;&#956;m threshold was selected based on prior similar studies [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>] and is consistent with our institutional practice standards. Exclusion criteria included the presence of other macular pathologies, such as age-related macular degeneration (AMD) or diabetic retinopathy (DR), significant systemic illnesses like severe cardiovascular, hepatic, or renal diseases, known hypersensitivity to the study medication, and any personal or medical concerns that could have affected treatment adherence or study participation. Additionally, all CRVO patients underwent baseline fluorescein angiography (FFA) to assess retinal perfusion, and those diagnosed with ischemic CRVO were excluded to ensure comparable baseline characteristics and to avoid confounding effects on outcomes.</p></sec><sec id="Sec4"><title>Randomization and blinding</title><p id="Par14">This study was conducted as an outcome assessor&#8211;blinded trial. Outcome assessors, statisticians, and data analysts were blinded to group allocation, while patients and the healthcare personnel administering the interventions were aware of treatment assignments due to the distinctive taste and preparation of the herbal decoction. In this study, a stratified randomization method was used to allocate participants into two groups in a 1:1 ratio, utilizing SPSS v26.0 (SPSS Inc, Chicago, IL, USA). The randomization process incorporated minimization and accounted for three key variables for stratification: sex (male/female), age (&gt;&#8201;50/&#8201;&#8804;&#8201;50&#160;years), and type of retinal vein occlusion (RVO) (CRVO/BRVO). A pre-determined random allocation sequence was generated and sealed in sequentially numbered opaque envelopes to ensure one-time randomization. A researcher, who was not involved in the intervention, monitored the allocation process to maintain impartiality. All personnel involved in the study, including outcome assessors, statisticians, and data analysts, remained blinded to group allocation, while those administering the intervention were informed of the group assignments.</p></sec><sec id="Sec5"><title>Interventions</title><p id="Par15">All eligible patients were randomly assigned in a 1:1 ratio using a random number table to one of two treatment groups: the monotherapy group, which received intravitreal injections of 0.5&#160;mg of ranibizumab alone, or the combination group, which received both intravitreal injections of 0.5&#160;mg of ranibizumab and daily consumption of Jueling Mingmu Decoction.</p><p id="Par16">The herbal components were sourced from certified suppliers, and all raw materials underwent authentication and quality control testing, including checks for heavy metals, pesticide residues, and microbial contamination. The decoction was prepared and packaged in standardized doses by a GMP-certified pharmaceutical company to ensure consistency and safety.</p><p id="Par17">For the first 3&#160;months, all patients received monthly intravitreal injections of 0.5&#160;mg ranibizumab. From months 4 to 12, patients were evaluated monthly, with additional ranibizumab injections administered if there was a loss of 5 or more letters of BCVA on the ETDRS chart compared to their highest previous score, or if residual macular edema was detected on OCT. Residual macular edema was defined as insufficient CST reduction following three intravitreal anti-VEGF injections, according to the criteria proposed by Sorour [<xref ref-type="bibr" rid="CR24">24</xref>]: a reduction in CST of&#8201;&lt;&#8201;10% for retinal thickness&#8201;&#8804;&#8201;400&#160;&#956;m,&#8201;&lt;&#8201;15% for 401&#8211;500&#160;&#956;m,&#8201;&lt;&#8201;20% for 501&#8211;600&#160;&#956;m, and&#8201;&lt;&#8201;25% for&#8201;&gt;&#8201;600&#160;&#956;m. Intravitreal injections were administered by ophthalmologists under topical anesthesia in a sterile operating room. Following skin preparation, 0.5&#160;mg (0.05&#160;mL) of ranibizumab (Lucentis&#174;; Novartis, Basel, Switzerland) was injected into the vitreous cavity through the pars plana using a 30-gauge needle. The injection site was gently compressed for one minute after needle withdrawal. Following the injection, patients were instructed to apply 0.3% levofloxacin eye drops four times daily for one week. For patients with intraocular pressure (IOP)&#8201;&#8805;&#8201;22&#160;mmHg, topical antiglaucoma medications, either single or in combination, were prescribed.</p><p id="Par18">Patients in the combination group consumed 200&#160;mL of Jueling Mingmu Decoction once daily for the first month of treatment only. The decoction was formulated as a standardized granule extract, packaged in single-dose sachets, and dissolved in 50&#160;mL of hot water prior to ingestion. Each dose consisted of one sachet, administered once daily immediately after a meal. The use of any other TCM or modern Western medicine was strictly prohibited during the treatment period, in addition to the prescribed medications. Adherence was monitored through weekly telephone follow-up during the first month and sachet counts at scheduled visits. To assess safety, liver and renal function tests were performed at baseline and at 1, 3, and 6&#160;months after treatment for patients in the combination group.</p></sec><sec id="Sec6"><title>Efficacy evaluation</title><p id="Par19">Baseline data were collected on the duration of occlusion, history of prior eye diseases or interventions, and the presence of systemic conditions. Ophthalmic assessments included BCVA, IOP, and detailed anterior and posterior segment evaluations using indirect ophthalmoscopy, including fundus examination findings.</p><p id="Par20">The primary outcome was the mean number of intravitreal ranibizumab injections administered over 48&#160;weeks, compared between the two groups. Secondary outcomes included changes in BCVA and CST from baseline.</p><p id="Par21">Follow-up visits were conducted at weeks 4, 12, 24, 36, and 48. At each visit, BCVA was recorded, and comprehensive evaluations were performed, including slit-lamp examination, IOP measurement, fundus assessment, and OCT imaging.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par22">A comprehensive analysis was performed to describe the demographic and clinical characteristics of the patient population. The Shapiro&#8211;Wilk test was used to assess the normality of the variables. Continuous data were presented as mean&#8201;&#177;&#8201;standard deviation (SD), while categorical data were expressed as counts (percentages).</p><p id="Par23">Group comparisons were conducted using the independent samples t-test for normally distributed variables and the Mann&#8211;Whitney U test for non-normally distributed variables. Categorical variables were analyzed using the chi-square test. Changes in mean BCVA and CST before and after treatment within each group were evaluated using a paired Student&#8217;s t-test. All statistical tests were two-tailed, with a significance threshold set at 0.05. Data analysis was carried out using SPSS version 17 (IBM Corporation, Armonk, NY) following standard analytical procedures.</p></sec></sec><sec id="Sec8"><title>Results</title><p id="Par24">A total of 111 patients were randomized into the study, with 53 allocated to the monotherapy group and 58 to the combination group. Of these, 99 patients (89.2%) completed the trial, including 46 (86.8%) in the monotherapy group and 53 (91.4%) in the combination group (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Flow diagram for the study</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="10792_2025_3738_Fig1_HTML.jpg"/></fig></p><p id="Par25">The baseline characteristics of the patients are summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. No significant differences were identified between the two groups regarding age, gender, IOP, lens status, presence of diabetes mellitus or hypertension, BMI, symptom duration, baseline BCVA, CST, or the proportion of RVO types.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Comparison of baseline characteristics of the intervention and control groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Group</th><th align="left" colspan="1" rowspan="1">Combination therapy group</th><th align="left" colspan="1" rowspan="1">Intravitreal ranibizumab group</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Number of eyes</td><td align="left" colspan="1" rowspan="1">53</td><td align="left" colspan="1" rowspan="1">46</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1">Age (years) (Mean&#8201;&#177;&#8201;SD)</td><td align="left" colspan="1" rowspan="1">62.25&#8201;&#177;&#8201;15.14</td><td align="left" colspan="1" rowspan="1">63.43&#8201;&#177;&#8201;13.59</td><td align="left" colspan="1" rowspan="1">0.68<sup>&#8224;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Sex (n), male/female</td><td align="left" colspan="1" rowspan="1">27/26</td><td align="left" colspan="1" rowspan="1">22/24</td><td align="left" colspan="1" rowspan="1">0.76<sup>&#8225;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">IOP (mmHg) (Mean&#8201;&#177;&#8201;SD)</td><td align="left" colspan="1" rowspan="1">15.13&#8201;&#177;&#8201;3.11</td><td align="left" colspan="1" rowspan="1">14.26&#8201;&#177;&#8201;2.20</td><td align="left" colspan="1" rowspan="1">0.27<sup>&#167;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Lens status (n), phakic/IOL</td><td align="left" colspan="1" rowspan="1">46/7</td><td align="left" colspan="1" rowspan="1">39/7</td><td align="left" colspan="1" rowspan="1">0.78<sup>&#8225;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes Mellitus (%)</td><td align="left" colspan="1" rowspan="1">5(9.4)</td><td align="left" colspan="1" rowspan="1">5(10.9)</td><td align="left" colspan="1" rowspan="1">0.81<sup>&#8225;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension (%)</td><td align="left" colspan="1" rowspan="1">27(50.9)</td><td align="left" colspan="1" rowspan="1">23(50.0)</td><td align="left" colspan="1" rowspan="1">0.93<sup>&#8225;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">BMI (Mean&#8201;&#177;&#8201;SD)</td><td align="left" colspan="1" rowspan="1">23.72&#8201;&#177;&#8201;2.23</td><td align="left" colspan="1" rowspan="1">23.54&#8201;&#177;&#8201;2.24</td><td align="left" colspan="1" rowspan="1">0.37<sup>&#167;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Duration of symptoms (weeks) (Mean&#8201;&#177;&#8201;SD)</td><td align="left" colspan="1" rowspan="1">15.92&#8201;&#177;&#8201;17.90</td><td align="left" colspan="1" rowspan="1">11.11&#8201;&#177;&#8201;13.93</td><td align="left" colspan="1" rowspan="1">0.22<sup>&#167;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">BCVA (LogMAR) (Mean&#8201;&#177;&#8201;SD)</td><td align="left" colspan="1" rowspan="1">1.02&#8201;&#177;&#8201;0.33</td><td align="left" colspan="1" rowspan="1">0.95&#8201;&#177;&#8201;0.37</td><td align="left" colspan="1" rowspan="1">0.32<sup>&#167;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">CST (um) (Mean&#8201;&#177;&#8201;SD)</td><td align="left" colspan="1" rowspan="1">706.23&#8201;&#177;&#8201;235.53</td><td align="left" colspan="1" rowspan="1">653.63&#8201;&#177;&#8201;216.34</td><td align="left" colspan="1" rowspan="1">0.19<sup>&#167;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Type of RVO (n), CRVO/BRVO</td><td align="left" colspan="1" rowspan="1">11/42</td><td align="left" colspan="1" rowspan="1">10/36</td><td align="left" colspan="1" rowspan="1">0.91<sup>&#8225;</sup></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">SD</italic>, standard deviation; <italic toggle="yes">n</italic>, number; <italic toggle="yes">IOP</italic>, intraocular pressure; <italic toggle="yes">IOL</italic>, intraocular lens; <italic toggle="yes">BMI</italic>, body mass index; <italic toggle="yes">BCVA</italic>, best-corrected visual acuity; <italic toggle="yes">LogMAR</italic>, logarithm of minimum angle of resolution; <italic toggle="yes">CST</italic>, Central subfield fovea thickness; <italic toggle="yes">RVO</italic>, retinal vein occlusion; <italic toggle="yes">CRVO</italic>, central retinal vein occlusion; <italic toggle="yes">BRVO</italic>, branch retinal vein occlusion</p><p><sup>&#8224;</sup>
<italic toggle="yes">p</italic>&#160;values were derived by Independent Samples <italic toggle="yes">t</italic>-tests</p><p><sup>&#8225;</sup>
<italic toggle="yes">p</italic>&#160;values were derived by Pearson&#8217;s chi-square tests</p><p><sup>&#167;</sup>
<italic toggle="yes">p</italic>&#160;value was derived by Mann&#8211;Whitney U test</p></table-wrap-foot></table-wrap></p><sec id="Sec9"><title>Primary outcome</title><p id="Par26">At 48&#160;weeks, there was no significant difference in the number of intravitreal injections between the two groups. The monotherapy group received an average of 4.35&#8201;&#177;&#8201;1.73 injections, while the combination group received 4.64&#8201;&#177;&#8201;1.92 injections (P&#8201;=&#8201;0.471). Similarly, subgroup analysis showed no statistically significant differences (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Comparison of the number of intravitreal injections, visual, and anatomic outcomes at 48&#160;weeks between patients treated with intravitreal injection monotherapy and those treated with combination therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">outcome</th><th align="left" colspan="3" rowspan="1">Retinal Vein Occlusion</th><th align="left" colspan="3" rowspan="1">Branch Retinal Vein Occlusion</th><th align="left" colspan="3" rowspan="1">Central Retinal Vein Occlusion</th></tr><tr><th align="left" colspan="1" rowspan="1">Monotherapy</th><th align="left" colspan="1" rowspan="1">Combination therapy</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th><th align="left" colspan="1" rowspan="1">Monotherapy</th><th align="left" colspan="1" rowspan="1">Combination therapy</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th><th align="left" colspan="1" rowspan="1">Monotherapy</th><th align="left" colspan="1" rowspan="1">Combination therapy</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Number of intravitreal injections (Mean&#8201;&#177;&#8201;SD)</td><td char="." align="char" colspan="1" rowspan="1">4.35&#8201;&#177;&#8201;1.73</td><td char="." align="char" colspan="1" rowspan="1">4.64&#8201;&#177;&#8201;1.92</td><td char="." align="char" colspan="1" rowspan="1">0.471</td><td char="." align="char" colspan="1" rowspan="1">5.50&#8201;&#177;&#8201;1.96</td><td char="." align="char" colspan="1" rowspan="1">5.55&#8201;&#177;&#8201;2.25</td><td char="." align="char" colspan="1" rowspan="1">0.918</td><td char="." align="char" colspan="1" rowspan="1">4.03&#8201;&#177;&#8201;1.54</td><td char="." align="char" colspan="1" rowspan="1">4.40&#8201;&#177;&#8201;1.78</td><td char="." align="char" colspan="1" rowspan="1">0.284</td></tr><tr><td align="left" colspan="1" rowspan="1">BCVA (LogMAR) (Mean&#8201;&#177;&#8201;SD)</td><td char="." align="char" colspan="1" rowspan="1">0.69&#8201;&#177;&#8201;0.38</td><td char="." align="char" colspan="1" rowspan="1">0.57&#8201;&#177;&#8201;0.44</td><td char="." align="char" colspan="1" rowspan="1">0.041</td><td char="." align="char" colspan="1" rowspan="1">1.12&#8201;&#177;&#8201;0.39</td><td char="." align="char" colspan="1" rowspan="1">0.99&#8201;&#177;&#8201;0.47</td><td char="." align="char" colspan="1" rowspan="1">0.512</td><td char="." align="char" colspan="1" rowspan="1">0.57&#8201;&#177;&#8201;0.28</td><td char="." align="char" colspan="1" rowspan="1">0.46&#8201;&#177;&#8201;0.36</td><td char="." align="char" colspan="1" rowspan="1">0.031</td></tr><tr><td align="left" colspan="1" rowspan="1">CST (um) (Mean&#8201;&#177;&#8201;SD)</td><td char="." align="char" colspan="1" rowspan="1">346.07&#8201;&#177;&#8201;196.74</td><td char="." align="char" colspan="1" rowspan="1">262.87&#8201;&#177;&#8201;92.24</td><td char="." align="char" colspan="1" rowspan="1">0.048</td><td char="." align="char" colspan="1" rowspan="1">457.10&#8201;&#177;&#8201;264.45</td><td char="." align="char" colspan="1" rowspan="1">294.00&#8201;&#177;&#8201;149.16</td><td char="." align="char" colspan="1" rowspan="1">0.251</td><td char="." align="char" colspan="1" rowspan="1">315.22&#8201;&#177;&#8201;165.18</td><td char="." align="char" colspan="1" rowspan="1">254.71&#8201;&#177;&#8201;70.96</td><td char="." align="char" colspan="1" rowspan="1">0.102</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">SD</italic>, standard deviation; <italic toggle="yes">BCVA</italic>, best-corrected visual acuity; <italic toggle="yes">LogMAR</italic>, logarithm of minimum angle of resolution; <italic toggle="yes">CST</italic>, Central subfield fovea thickness</p><p><italic toggle="yes">p</italic>&#160;value was derived by Mann&#8211;Whitney U test</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Secondary outcomes</title><p id="Par27">The mean BCVA improved significantly from baseline in all treatment groups. At the end of the 48-week period, BCVA in the monotherapy group improved from 0.95&#8201;&#177;&#8201;0.37 to 0.69&#8201;&#177;&#8201;0.38 (P&#8201;=&#8201;0.000), while the combination group showed greater improvement, from 1.02&#8201;&#177;&#8201;0.33 to 0.57&#8201;&#177;&#8201;0.44 (P&#8201;=&#8201;0.000). During the 48-week follow-up, a statistically significant difference in BCVA between the two groups was observed only at 48&#160;weeks (P&#8201;=&#8201;0.041, Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). No significant differences were found at other time points (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A). Subgroup analysis showed no significant difference in BCVA between the two groups among patients with CRVO throughout the 48&#160;weeks (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A). For patients with BRVO, BCVA was similar between the two groups during the first 36&#160;weeks, but the combination group demonstrated superior improvement at 48&#160;weeks (P&#8201;=&#8201;0.031, Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>C, Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Changes in BCVA and CST in RVO Patients During the 48-Week Follow-Up in the Monotherapy and Combination Therapy Groups. A: Changes in BCVA; B: Changes in CST (RVO&#8201;=&#8201;Retinal Vein Occlusion; BCVA&#8201;=&#8201;Best-Corrected Visual Acuity; CST&#8201;=&#8201;Central Subfield Fovea Thickness; * indicates statistical significance)</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="10792_2025_3738_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Subgroup Analysis: Changes in BCVA and CST in BRVO and CRVO Patients During the 48-Week Follow-Up in the Monotherapy and Combination Therapy Groups. A: Changes in BCVA in CRVO Patients; B: Changes in CST in CRVO Patients; C: Changes in BCVA in BRVO Patients; D: Changes in CST in BRVO Patients. (CRVO&#8201;=&#8201;Central Retinal Vein Occlusion; BRVO&#8201;=&#8201;Branch Retinal Vein Occlusion; BCVA&#8201;=&#8201;Best-Corrected Visual Acuity; CST&#8201;=&#8201;Central Subfield Fovea Thickness; * indicates statistical significance)</p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="10792_2025_3738_Fig3_HTML.jpg"/></fig></p><p id="Par28">After 48&#160;weeks of treatment, CST decreased significantly in both groups. In the monotherapy group, CST reduced from 653.63&#8201;&#177;&#8201;216.34 to 332.48&#8201;&#177;&#8201;184.27 (P&#8201;=&#8201;0.000), while in the combination group, it decreased from 706.23&#8201;&#177;&#8201;235.53 to 262.87&#8201;&#177;&#8201;92.24 (P&#8201;=&#8201;0.000). At all follow-up time points within the 48-week period, there was no statistically significant difference in CST between the two groups (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Subgroup analysis showed that among BRVO patients, the CST in the combination group was significantly lower than that in the monotherapy group at 36&#160;weeks (P&#8201;=&#8201;0.018, Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>D). However, no significant differences in CST were observed between the two groups or among CRVO patients at other time points (Figs.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B and 3D).</p></sec><sec id="Sec11"><title>Safety</title><p id="Par29">No treatment-related adverse events were observed in either group during the clinical observation period. Throughout the 12-month follow-up, no major ocular complications, including elevated intraocular pressure, retinal detachment, intraocular inflammation, or vascular events, were reported in either group. In the combination group, liver and renal function tests conducted at baseline and at 1, 3, and 6&#160;months post-treatment revealed no clinically significant abnormalities.</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par30">This randomized, outcome assessor&#8211;blinded trial evaluated the efficacy of combining Jueling Mingmu Decoction with intravitreal ranibizumab injections for treating ME associated with RVO. The findings revealed that while the combination therapy offered certain advantages in improving secondary outcomes&#8212;such as better BCVA in BRVO patients at 48&#160;weeks and greater CST reduction at 36&#160;weeks&#8212;it did not significantly reduce the number of required intravitreal injections compared to monotherapy.</p><p id="Par31">Current intravitreal therapies for RVO-related ME, when administered consistently and over an adequate duration, effectively sustain initial improvements [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. However, these interventions primarily address the consequences of venous outflow obstruction without targeting the underlying multifactorial causes. Factors such as elevated central venous pressure, cytokine upregulation, and inflammatory processes are thought to contribute to RVO pathology [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Given the complex nature of RVO, a treatment approach that simultaneously targets multiple pathways may more effectively delay disease progression and improve clinical outcomes.</p><p id="Par32">TCM differs from Western medicine in its use of complex formulations composed of multiple herbs, each containing various active ingredients. For example, Poria, a commonly used TCM herb, is known for its ability to reduce swelling and aid in the absorption of retinal hemorrhage, thereby alleviating macular edema. Salvia miltiorrhiza, another key component, has long been used to treat microcirculatory disturbances. Its active compounds, such as salvianolic acid B and protocatechuic aldehyde, can promote collateral circulation, potentially improving visual outcomes and reducing the frequency of injections. These ingredients collectively act on multiple biological pathways, forming a synergistic network of therapeutic effects. Some previous studies have shown that some TCM treatment combined with conventional treatment could have certain advantages [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par33">The BCVA and CST improvements observed in both groups underscore the well-established efficacy of anti-VEGF agents as the first-line treatment for RVO-related macular edema. However, BRVO patients in the combination group exhibited greater BCVA improvement at 48&#160;weeks and more pronounced CST reduction at 36&#160;weeks, suggesting that Jueling Mingmu Decoction may provide complementary benefits. By targeting pathways beyond VEGF inhibition&#8212;such as enhancing blood circulation, reducing retinal edema, and possibly exhibiting anti-inflammatory and diuretic properties&#8212;traditional Chinese medicine could address additional aspects of the disease process. These effects may optimize treatment outcomes by adopting a multi-pathway approach, as proposed in the previous studies [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Jueling Mingmu Decoction likely acts as an adjunctive therapy, targeting inflammation, microcirculatory dysfunction, and edema rather than exerting a direct anti-VEGF effect. This multi-pathway action complements ranibizumab and may partly explain the functional and anatomical benefits observed in BRVO patients. The importance of inflammation control in RVO has also been highlighted in recent study [<xref ref-type="bibr" rid="CR32">32</xref>], which demonstrated the efficacy of long-term dexamethasone implant monotherapy. These findings underscore the potential value of incorporating anti-inflammatory strategies, including TCM formulations, into RVO management. The more pronounced improvements in BRVO patients compared to CRVO patients may be attributed to the relatively less severe retinal obstruction in BRVO, allowing combined treatment to exhibit a more noticeable therapeutic effect. In contrast, CRVO patients, with more severe retinal blockage and poorer baseline vision, may not experience distinguishable benefits from the combination therapy, masking any potential differences in treatment efficacy. As in previous study [<xref ref-type="bibr" rid="CR33">33</xref>], addition of scatter photocoagulation to ranibizumab might help slow the progression of non-perfusion in patients with BRVO, but not in those with CRVO.</p><p id="Par34">Despite these promising findings, the study did not show a significant reduction in the number of ranibizumab injections required in the combination group. This aligns with previous research, which indicates that adjunct therapies, such as retinal laser treatment or anti-inflammatory treatments [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], often do not lead to a reduction in injection frequency. The financial and logistical burdens associated with frequent anti-VEGF injections remain a significant challenge for patients, highlighting the need for alternative or complementary treatment options.</p><p id="Par35">This study has several strengths, including its robust design, use of stratified randomization, and adherence to established clinical protocols. However, it also has some limitations. First, although the outcome assessor&#8211;blinded design reduced the risk of bias by ensuring that assessors and data analysts were blinded, it cannot fully eliminate potential bias. Second, the 48-week follow-up period limits the ability to evaluate long-term outcomes and safety. Third, the study was conducted at a single center with a relatively small sample size, particularly in the CRVO subgroup, where only 10 patients were included in each group, potentially limiting the statistical power and generalizability of the findings. Fourth, the timing of the most recent ranibizumab injection prior to each follow-up visit was not systematically documented; therefore, some of the observed CST reductions&#8212;especially at 36&#160;weeks&#8212;may partly reflect short-term effects of recent injections rather than sustained anatomical improvement. These limitations should be considered when interpreting the results, and larger multicenter studies with longer follow-up are warranted.</p><p id="Par36">Future studies should explore the long-term efficacy and safety of combining TCM formulations with anti-VEGF therapy in larger, multicenter trials. Investigating the molecular mechanisms underlying the effects of Jueling Mingmu Decoction could provide deeper insights into its therapeutic potential and inform the development of novel treatment strategies for RVO-related ME. Additionally, cost-effectiveness analyses are needed to evaluate the feasibility of incorporating TCM into standard clinical practice.</p><p id="Par37">In conclusion, this study suggests that the combination of Jueling Mingmu Decoction with ranibizumab is a potentially effective treatment for improving visual and anatomical outcomes in patients with RVO-related ME, particularly in BRVO patients. While the results are encouraging, further research is necessary to confirm these findings and refine treatment protocols.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We extend our sincere gratitude to all research assistants and nursing staff who played pivotal roles in the practical organization and execution of this study.</p></ack><notes notes-type="author-contribution"><title>Author Contribution</title><p>WHY conceptualized and designed the study. ZHS drafted the main manuscript text. ZY collected the data, and ZHS verified it. ZHS conducted the statistical analyses. All authors critically reviewed and revised the manuscript before submission.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The research was financially supported by the Jinhua Traditional Chinese Medicine Science and Technology Research Program (2023KY34).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data supporting the study results can be obtained from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interests</title><p id="Par38">The authors declare that they have no competing interests.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par39">Not applicable.</p></notes><notes id="FPar3"><title>Ethics approval</title><p id="Par40">Have been granted by the Institutional Ethical Committee of Dongyang People's Hospital, with reference number Dongrenyi 2023-YX-346. Informed consent will be obtained from all study participants upon their recruitment.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>IU</given-names></name><name name-style="western"><surname>Campochiaro</surname><given-names>PA</given-names></name><name name-style="western"><surname>Newman</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Biousse</surname><given-names>V</given-names></name></person-group><article-title>Retinal vascular occlusions</article-title><source>Lancet</source><year>2020</year><volume>396</volume><issue>10266</issue><fpage>1927</fpage><lpage>1940</lpage><pub-id pub-id-type="pmid">33308475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31559-2</pub-id><pub-id pub-id-type="pmcid">PMC9546635</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Scott IU, Campochiaro PA, Newman NJ, Biousse V (2020) Retinal vascular occlusions. Lancet 396(10266):1927&#8211;1940<pub-id pub-id-type="pmid">33308475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31559-2</pub-id><pub-id pub-id-type="pmcid">PMC9546635</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>S</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>RL</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>N</given-names></name><name name-style="western"><surname>Lim</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>P</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>JW</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H</given-names></name><name name-style="western"><surname>Wong</surname><given-names>TY</given-names></name></person-group><article-title>International eye disease C: The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia</article-title><source>Ophthalmology</source><year>2010</year><volume>117</volume><issue>2</issue><fpage>313</fpage><lpage>319 e311</lpage><pub-id pub-id-type="pmid">20022117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2009.07.017</pub-id><pub-id pub-id-type="pmcid">PMC2945292</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY (2010) International eye disease C: The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117(2):313-319 e311<pub-id pub-id-type="pmid">20022117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2009.07.017</pub-id><pub-id pub-id-type="pmcid">PMC2945292</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalva</surname><given-names>P</given-names></name><name name-style="western"><surname>Akram</surname><given-names>R</given-names></name><name name-style="western"><surname>Zuberi</surname><given-names>HZ</given-names></name><name name-style="western"><surname>Kooner</surname><given-names>KS</given-names></name></person-group><article-title>Prevalence and risk factors of retinal vein occlusion in the United States: the national health and nutrition examination survey, 2005 to 2008</article-title><source>Proc (Bayl Univ Med Cent)</source><year>2023</year><volume>36</volume><issue>3</issue><fpage>335</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">37091777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08998280.2023.2173938</pub-id><pub-id pub-id-type="pmcid">PMC10120443</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Kalva P, Akram R, Zuberi HZ, Kooner KS (2023) Prevalence and risk factors of retinal vein occlusion in the United States: the national health and nutrition examination survey, 2005 to 2008. Proc (Bayl Univ Med Cent) 36(3):335&#8211;340<pub-id pub-id-type="pmid">37091777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08998280.2023.2173938</pub-id><pub-id pub-id-type="pmcid">PMC10120443</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Cochran ML, Mahabadi N, Czyz CN (2024) Branch retinal vein occlusion. In: StatPearls<italic toggle="yes">.</italic> edn. Treasure Island (FL).<pub-id pub-id-type="pmid">30570991</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomel</surname><given-names>N</given-names></name><name name-style="western"><surname>D'Aloisio</surname><given-names>R</given-names></name><name name-style="western"><surname>Wattad</surname><given-names>A</given-names></name><name name-style="western"><surname>Mastropasqua</surname><given-names>R</given-names></name><name name-style="western"><surname>Formenti</surname><given-names>F</given-names></name><name name-style="western"><surname>Loewenstein</surname><given-names>A</given-names></name><name name-style="western"><surname>Iglicki</surname><given-names>M</given-names></name><name name-style="western"><surname>Zur</surname><given-names>D</given-names></name></person-group><article-title>Good initial visual acuity in patients with macular edema due to retinal vein occlusion - management and outcomes</article-title><source>Retina</source><year>2024</year><pub-id pub-id-type="doi">10.1097/IAE.0000000000004244</pub-id><pub-id pub-id-type="pmid">39121498</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Gomel N, D&#8217;Aloisio R, Wattad A, Mastropasqua R, Formenti F, Loewenstein A, Iglicki M, Zur D (2024) Good initial visual acuity in patients with macular edema due to retinal vein occlusion - management and outcomes. Retina. 10.1097/IAE.0000000000004244<pub-id pub-id-type="pmid">39121498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/IAE.0000000000004244</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parodi</surname><given-names>MB</given-names></name><name name-style="western"><surname>Spasse</surname><given-names>S</given-names></name><name name-style="western"><surname>Iacono</surname><given-names>P</given-names></name><name name-style="western"><surname>Di Stefano</surname><given-names>G</given-names></name><name name-style="western"><surname>Canziani</surname><given-names>T</given-names></name><name name-style="western"><surname>Ravalico</surname><given-names>G</given-names></name></person-group><article-title>Subthreshold grid laser treatment of macular edema secondary to branch retinal vein occlusion with micropulse infrared (810 nanometer) diode laser</article-title><source>Ophthalmology</source><year>2006</year><volume>113</volume><issue>12</issue><fpage>2237</fpage><lpage>2242</lpage><pub-id pub-id-type="pmid">16996596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2006.05.056</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Parodi MB, Spasse S, Iacono P, Di Stefano G, Canziani T, Ravalico G (2006) Subthreshold grid laser treatment of macular edema secondary to branch retinal vein occlusion with micropulse infrared (810 nanometer) diode laser. Ophthalmology 113(12):2237&#8211;2242<pub-id pub-id-type="pmid">16996596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2006.05.056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerding</surname><given-names>H</given-names></name><name name-style="western"><surname>Mones</surname><given-names>J</given-names></name><name name-style="western"><surname>Tadayoni</surname><given-names>R</given-names></name><name name-style="western"><surname>Boscia</surname><given-names>F</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>I</given-names></name><name name-style="western"><surname>Priglinger</surname><given-names>S</given-names></name></person-group><article-title>Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel</article-title><source>Br J Ophthalmol</source><year>2015</year><volume>99</volume><issue>3</issue><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">25075121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bjophthalmol-2014-305041</pub-id><pub-id pub-id-type="pmcid">PMC4345884</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Gerding H, Mones J, Tadayoni R, Boscia F, Pearce I, Priglinger S (2015) Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel. Br J Ophthalmol 99(3):297&#8211;304<pub-id pub-id-type="pmid">25075121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bjophthalmol-2014-305041</pub-id><pub-id pub-id-type="pmcid">PMC4345884</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>YH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name><name name-style="western"><surname>Bae</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>DJ</given-names></name></person-group><article-title>Effect of alternate treatment with intravitreal corticosteroid and anti-VEGF for Macular Edema secondary to retinal vein occlusion</article-title><source>J Ophthalmol</source><year>2021</year><volume>2021</volume><fpage>5948113</fpage><pub-id pub-id-type="pmid">34621544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/5948113</pub-id><pub-id pub-id-type="pmcid">PMC8492286</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Bae YH, Kim SM, Kim JY, Bae SH, Kim H, Ma DJ (2021) Effect of alternate treatment with intravitreal corticosteroid and anti-VEGF for Macular Edema secondary to retinal vein occlusion. J Ophthalmol 2021:5948113<pub-id pub-id-type="pmid">34621544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/5948113</pub-id><pub-id pub-id-type="pmcid">PMC8492286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt-Erfurth</surname><given-names>U</given-names></name><name name-style="western"><surname>Garcia-Arumi</surname><given-names>J</given-names></name><name name-style="western"><surname>Gerendas</surname><given-names>BS</given-names></name><name name-style="western"><surname>Midena</surname><given-names>E</given-names></name><name name-style="western"><surname>Sivaprasad</surname><given-names>S</given-names></name><name name-style="western"><surname>Tadayoni</surname><given-names>R</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>S</given-names></name><name name-style="western"><surname>Loewenstein</surname><given-names>A</given-names></name></person-group><article-title>Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA)</article-title><source>Ophthalmologica</source><year>2019</year><volume>242</volume><issue>3</issue><fpage>123</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">31412332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000502041</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, Wolf S, Loewenstein A (2019) Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica 242(3):123&#8211;162<pub-id pub-id-type="pmid">31412332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000502041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flaxel</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Adelman</surname><given-names>RA</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>ST</given-names></name><name name-style="western"><surname>Fawzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Lim</surname><given-names>JI</given-names></name><name name-style="western"><surname>Vemulakonda</surname><given-names>GA</given-names></name><name name-style="western"><surname>Ying</surname><given-names>GS</given-names></name></person-group><article-title>Retinal vein occlusions preferred practice pattern(R)</article-title><source>Ophthalmology</source><year>2020</year><volume>127</volume><issue>2</issue><fpage>P288</fpage><lpage>P320</lpage><pub-id pub-id-type="pmid">31757503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2019.09.029</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS (2020) Retinal vein occlusions preferred practice pattern(R). Ophthalmology 127(2):P288&#8211;P320<pub-id pub-id-type="pmid">31757503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2019.09.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhisitkul</surname><given-names>RB</given-names></name><name name-style="western"><surname>Blotner</surname><given-names>S</given-names></name><name name-style="western"><surname>Steffen</surname><given-names>V</given-names></name><name name-style="western"><surname>Haskova</surname><given-names>Z</given-names></name></person-group><article-title>Clinical trial versus real-world outcomes with anti-VEGF therapy for central retinal vein occlusion</article-title><source>Invest Ophthalmol Vis Sci</source><year>2020</year><volume>61</volume><issue>7</issue><fpage>1304</fpage><lpage>1304</lpage></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Bhisitkul RB, Blotner S, Steffen V, Haskova Z (2020) Clinical trial versus real-world outcomes with anti-VEGF therapy for central retinal vein occlusion. Invest Ophthalmol Vis Sci 61(7):1304&#8211;1304</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciulla</surname><given-names>T</given-names></name><name name-style="western"><surname>Pollack</surname><given-names>JS</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DF</given-names></name></person-group><article-title>Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes</article-title><source>Br J Ophthalmol</source><year>2021</year><volume>105</volume><issue>12</issue><fpage>1696</fpage><lpage>1704</lpage><pub-id pub-id-type="pmid">33055088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bjophthalmol-2020-317337</pub-id><pub-id pub-id-type="pmcid">PMC8639936</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Ciulla T, Pollack JS, Williams DF (2021) Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes. Br J Ophthalmol 105(12):1696&#8211;1704<pub-id pub-id-type="pmid">33055088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bjophthalmol-2020-317337</pub-id><pub-id pub-id-type="pmcid">PMC8639936</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tadayoni</surname><given-names>R</given-names></name><name name-style="western"><surname>Waldstein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Boscia</surname><given-names>F</given-names></name><name name-style="western"><surname>Gerding</surname><given-names>H</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>I</given-names></name><name name-style="western"><surname>Priglinger</surname><given-names>S</given-names></name><name name-style="western"><surname>Wenzel</surname><given-names>A</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>E</given-names></name><name name-style="western"><surname>Gekkieva</surname><given-names>M</given-names></name><name name-style="western"><surname>Pilz</surname><given-names>S</given-names></name><etal/></person-group><article-title>Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER</article-title><source>Ophthalmology</source><year>2016</year><volume>123</volume><issue>6</issue><fpage>1332</fpage><lpage>1344</lpage><pub-id pub-id-type="pmid">27039022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2016.02.030</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I, Priglinger S, Wenzel A, Barnes E, Gekkieva M, Pilz S et al (2016) Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology 123(6):1332&#8211;1344<pub-id pub-id-type="pmid">27039022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2016.02.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campochiaro</surname><given-names>PA</given-names></name><name name-style="western"><surname>Hafiz</surname><given-names>G</given-names></name><name name-style="western"><surname>Mir</surname><given-names>TA</given-names></name><name name-style="western"><surname>Scott</surname><given-names>AW</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>S</given-names></name><name name-style="western"><surname>Zimmer-Galler</surname><given-names>I</given-names></name><name name-style="western"><surname>Sodhi</surname><given-names>A</given-names></name><name name-style="western"><surname>Duh</surname><given-names>E</given-names></name><name name-style="western"><surname>Ying</surname><given-names>H</given-names></name><name name-style="western"><surname>Wenick</surname><given-names>A</given-names></name><etal/></person-group><article-title>Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial</article-title><source>Ophthalmology</source><year>2015</year><volume>122</volume><issue>7</issue><fpage>1426</fpage><lpage>1437</lpage><pub-id pub-id-type="pmid">25972260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2015.04.006</pub-id><pub-id pub-id-type="pmcid">PMC10020833</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, Sodhi A, Duh E, Ying H, Wenick A et al (2015) Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology 122(7):1426&#8211;1437<pub-id pub-id-type="pmid">25972260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2015.04.006</pub-id><pub-id pub-id-type="pmcid">PMC10020833</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soliman</surname><given-names>MK</given-names></name><name name-style="western"><surname>Zarranz-Ventura</surname><given-names>J</given-names></name><name name-style="western"><surname>Chakravarthy</surname><given-names>U</given-names></name><name name-style="western"><surname>McKibbin</surname><given-names>M</given-names></name><name name-style="western"><surname>Brand</surname><given-names>C</given-names></name><name name-style="western"><surname>Menon</surname><given-names>G</given-names></name><name name-style="western"><surname>Cilliers</surname><given-names>H</given-names></name><name name-style="western"><surname>Natha</surname><given-names>S</given-names></name><name name-style="western"><surname>Ross</surname><given-names>A</given-names></name><name name-style="western"><surname>Sarhan</surname><given-names>M</given-names></name><etal/></person-group><article-title>United Kingdom database study of intravitreal dexamethasone implant (Ozurdex) for macular edema related to retinal vein occlusion</article-title><source>Retina</source><year>2023</year><volume>43</volume><issue>4</issue><fpage>679</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">36729561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/IAE.0000000000003698</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Soliman MK, Zarranz-Ventura J, Chakravarthy U, McKibbin M, Brand C, Menon G, Cilliers H, Natha S, Ross A, Sarhan M et al (2023) United Kingdom database study of intravitreal dexamethasone implant (Ozurdex) for macular edema related to retinal vein occlusion. Retina 43(4):679&#8211;687<pub-id pub-id-type="pmid">36729561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/IAE.0000000000003698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pranata</surname><given-names>R</given-names></name><name name-style="western"><surname>Vania</surname><given-names>A</given-names></name><name name-style="western"><surname>Vania</surname><given-names>R</given-names></name><name name-style="western"><surname>Victor</surname><given-names>AA</given-names></name></person-group><article-title>Intravitreal ranibizumab versus dexamethasone implant in macular edema due to branch retinal vein occlusion: systematic review and meta-analysis</article-title><source>Eur J Ophthalmol</source><year>2021</year><volume>31</volume><issue>4</issue><fpage>1907</fpage><lpage>1914</lpage><pub-id pub-id-type="pmid">32757629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1120672120947595</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Pranata R, Vania A, Vania R, Victor AA (2021) Intravitreal ranibizumab versus dexamethasone implant in macular edema due to branch retinal vein occlusion: systematic review and meta-analysis. Eur J Ophthalmol 31(4):1907&#8211;1914<pub-id pub-id-type="pmid">32757629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1120672120947595</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>XY</given-names></name><name name-style="western"><surname>Hu</surname><given-names>XF</given-names></name><name name-style="western"><surname>Qin</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Ma</surname><given-names>JX</given-names></name><name name-style="western"><surname>Liu</surname><given-names>QP</given-names></name><name name-style="western"><surname>Qin</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>JM</given-names></name></person-group><article-title>Comparison of intravitreal aflibercept and dexamethasone implant in the treatment of macular edema associated with diabetic retinopathy or retinal vein occlusion: a meta-analysis and systematic review</article-title><source>Int J Ophthalmol</source><year>2022</year><volume>15</volume><issue>9</issue><fpage>1511</fpage><lpage>1519</lpage><pub-id pub-id-type="pmid">36124196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18240/ijo.2022.09.15</pub-id><pub-id pub-id-type="pmcid">PMC9453398</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Qiu XY, Hu XF, Qin YZ, Ma JX, Liu QP, Qin L, Li JM (2022) Comparison of intravitreal aflibercept and dexamethasone implant in the treatment of macular edema associated with diabetic retinopathy or retinal vein occlusion: a meta-analysis and systematic review. Int J Ophthalmol 15(9):1511&#8211;1519<pub-id pub-id-type="pmid">36124196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18240/ijo.2022.09.15</pub-id><pub-id pub-id-type="pmcid">PMC9453398</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>J</given-names></name><name name-style="western"><surname>Gong</surname><given-names>D</given-names></name><name name-style="western"><surname>Duan</surname><given-names>L</given-names></name><name name-style="western"><surname>Tang</surname><given-names>R</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>A multidimensional perspective on <italic toggle="yes">Poria cocos</italic>, an ancient fungal traditional Chinese medicine</article-title><source>J Ethnopharmacol</source><year>2025</year><volume>348</volume><fpage>119869</fpage><pub-id pub-id-type="pmid">40280371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2025.119869</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Lei J, Gong D, Duan L, Tang R, Gu W, Zhang F, Zhao Y, Zhang M, Yang X, Yu J (2025) A multidimensional perspective on <italic toggle="yes">Poria cocos</italic>, an ancient fungal traditional Chinese medicine. J Ethnopharmacol 348:119869<pub-id pub-id-type="pmid">40280371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2025.119869</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>B</given-names></name><name name-style="western"><surname>Mei</surname><given-names>X</given-names></name><name name-style="western"><surname>Ji</surname><given-names>L</given-names></name></person-group><article-title>Uncovering the potential mechanism and bioactive compounds of Salviae Miltiorrhizae Radix et Rhizoma in attenuating diabetic retinopathy</article-title><source>Phytomedicine</source><year>2025</year><volume>139</volume><fpage>156461</fpage><pub-id pub-id-type="pmid">39986223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2025.156461</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Dong S, Zhang Y, Xie Y, Ouyang H, Zhou S, Shi J, Lu B, Mei X, Ji L (2025) Uncovering the potential mechanism and bioactive compounds of Salviae Miltiorrhizae Radix et Rhizoma in attenuating diabetic retinopathy. Phytomedicine 139:156461<pub-id pub-id-type="pmid">39986223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2025.156461</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nie</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J</given-names></name><etal/></person-group><article-title><italic toggle="yes">Fructus lycii</italic> and <italic toggle="yes">Salvia miltiorrhiza</italic> Bunge extract attenuate oxidative stress-induced photoreceptor ferroptosis in retinitis pigmentosa</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>167</volume><fpage>115547</fpage><pub-id pub-id-type="pmid">37741257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2023.115547</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Yang Y, Wang Y, Deng Y, Lu J, Xiao L, Li J, Zhou Y, Nie F, Chen X, Peng J et al (2023) <italic toggle="yes">Fructus lycii</italic> and <italic toggle="yes">Salvia miltiorrhiza</italic> Bunge extract attenuate oxidative stress-induced photoreceptor ferroptosis in retinitis pigmentosa. Biomed Pharmacother 167:115547<pub-id pub-id-type="pmid">37741257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2023.115547</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>P</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>An</surname><given-names>J</given-names></name></person-group><article-title>Therapeutic effect of traditional Chinese medicine on a rat model of branch retinal vein occlusion</article-title><source>J Ophthalmol</source><year>2019</year><pub-id pub-id-type="doi">10.1155/2019/9521379</pub-id><pub-id pub-id-type="pmid">30906588</pub-id><pub-id pub-id-type="pmcid">PMC6398022</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Long P, Yan W, Liu J, Li M, Chen T, Zhang Z, An J (2019) Therapeutic effect of traditional Chinese medicine on a rat model of branch retinal vein occlusion. J Ophthalmol. 10.1155/2019/9521379<pub-id pub-id-type="pmid">30906588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2019/9521379</pub-id><pub-id pub-id-type="pmcid">PMC6398022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>B</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>Effect of Lingqi Huangban granule plus intravitreal ranibizumab on macular edema induced by retinal vein occlusion: a randomized controlled clinical trial</article-title><source>J Tradit Chin Med</source><year>2020</year><volume>40</volume><issue>2</issue><fpage>305</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">32242396</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Lu B, Wu X (2020) Effect of Lingqi Huangban granule plus intravitreal ranibizumab on macular edema induced by retinal vein occlusion: a randomized controlled clinical trial. J Tradit Chin Med 40(2):305&#8211;310<pub-id pub-id-type="pmid">32242396</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McAllister</surname><given-names>IL</given-names></name><name name-style="western"><surname>Smithies</surname><given-names>LA</given-names></name><name name-style="western"><surname>Chen</surname><given-names>FK</given-names></name><name name-style="western"><surname>Mackey</surname><given-names>DA</given-names></name><name name-style="western"><surname>Sanfilippo</surname><given-names>PG</given-names></name></person-group><article-title>Two-year efficacy of ranibizumab plus laser-induced chorioretinal anastomosis vs ranibizumab monotherapy for central retinal vein occlusion: a randomized clinical trial</article-title><source>JAMA Ophthalmol</source><year>2018</year><volume>136</volume><issue>12</issue><fpage>1391</fpage><lpage>1397</lpage><pub-id pub-id-type="pmid">30347030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaophthalmol.2018.4973</pub-id><pub-id pub-id-type="pmcid">PMC6583051</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">McAllister IL, Smithies LA, Chen FK, Mackey DA, Sanfilippo PG (2018) Two-year efficacy of ranibizumab plus laser-induced chorioretinal anastomosis vs ranibizumab monotherapy for central retinal vein occlusion: a randomized clinical trial. JAMA Ophthalmol 136(12):1391&#8211;1397<pub-id pub-id-type="pmid">30347030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaophthalmol.2018.4973</pub-id><pub-id pub-id-type="pmcid">PMC6583051</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorour</surname><given-names>OA</given-names></name><name name-style="western"><surname>Levine</surname><given-names>ES</given-names></name><name name-style="western"><surname>Baumal</surname><given-names>CR</given-names></name><name name-style="western"><surname>Elnahry</surname><given-names>AG</given-names></name><name name-style="western"><surname>Braun</surname><given-names>P</given-names></name><name name-style="western"><surname>Girgis</surname><given-names>J</given-names></name><name name-style="western"><surname>Waheed</surname><given-names>NK</given-names></name></person-group><article-title>Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods</article-title><source>Surv Ophthalmol</source><year>2023</year><volume>68</volume><issue>2</issue><fpage>147</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">36436614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.survophthal.2022.11.008</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Sorour OA, Levine ES, Baumal CR, Elnahry AG, Braun P, Girgis J, Waheed NK (2023) Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods. Surv Ophthalmol 68(2):147&#8211;174<pub-id pub-id-type="pmid">36436614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.survophthal.2022.11.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><collab>Larsen M, Waldstein SM, Priglinger S, Hykin P, Barnes E, Gekkieva M, Das Gupta A, Wenzel A, Mones J, Group CS</collab></person-group><article-title>Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the CRYSTAL study</article-title><source>Ophthalmol Retina</source><year>2018</year><volume>2</volume><issue>2</issue><fpage>134</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">31047340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oret.2017.05.016</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Larsen M, Waldstein SM, Priglinger S, Hykin P, Barnes E, Gekkieva M, Das Gupta A, Wenzel A, Mones J, Group CS (2018) Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the CRYSTAL study. Ophthalmol Retina 2(2):134&#8211;142<pub-id pub-id-type="pmid">31047340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oret.2017.05.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spooner</surname><given-names>KL</given-names></name><name name-style="western"><surname>Fraser-Bell</surname><given-names>S</given-names></name><name name-style="western"><surname>Hong</surname><given-names>T</given-names></name><name name-style="western"><surname>Wong</surname><given-names>JG</given-names></name><name name-style="western"><surname>Chang</surname><given-names>AA</given-names></name></person-group><article-title>Long-term outcomes of anti-VEGF treatment of retinal vein occlusion</article-title><source>Eye (Lond)</source><year>2022</year><volume>36</volume><issue>6</issue><fpage>1194</fpage><lpage>1201</lpage><pub-id pub-id-type="pmid">34117379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41433-021-01620-z</pub-id><pub-id pub-id-type="pmcid">PMC9151794</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Spooner KL, Fraser-Bell S, Hong T, Wong JG, Chang AA (2022) Long-term outcomes of anti-VEGF treatment of retinal vein occlusion. Eye (Lond) 36(6):1194&#8211;1201<pub-id pub-id-type="pmid">34117379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41433-021-01620-z</pub-id><pub-id pub-id-type="pmcid">PMC9151794</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McAllister</surname><given-names>IL</given-names></name><name name-style="western"><surname>Tan</surname><given-names>MH</given-names></name><name name-style="western"><surname>Smithies</surname><given-names>LA</given-names></name><name name-style="western"><surname>Wong</surname><given-names>WL</given-names></name></person-group><article-title>The effect of central retinal venous pressure in patients with central retinal vein occlusion and a high mean area of nonperfusion</article-title><source>Ophthalmology</source><year>2014</year><volume>121</volume><issue>11</issue><fpage>2228</fpage><lpage>2236</lpage><pub-id pub-id-type="pmid">25037752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2014.05.031</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">McAllister IL, Tan MH, Smithies LA, Wong WL (2014) The effect of central retinal venous pressure in patients with central retinal vein occlusion and a high mean area of nonperfusion. Ophthalmology 121(11):2228&#8211;2236<pub-id pub-id-type="pmid">25037752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2014.05.031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinah</surname><given-names>C</given-names></name><name name-style="western"><surname>Chang</surname><given-names>A</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>WW</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wong</surname><given-names>D</given-names></name><name name-style="western"><surname>Saffar</surname><given-names>I</given-names></name></person-group><article-title>What is occluding our understanding of retinal vein occlusion?</article-title><source>Ophthalmol Ther</source><year>2024</year><volume>13</volume><issue>12</issue><fpage>3025</fpage><lpage>3034</lpage><pub-id pub-id-type="pmid">39387960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40123-024-01042-6</pub-id><pub-id pub-id-type="pmcid">PMC11564720</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Dinah C, Chang A, Lee J, Li WW, Singh R, Wu L, Wong D, Saffar I (2024) What is occluding our understanding of retinal vein occlusion? Ophthalmol Ther 13(12):3025&#8211;3034<pub-id pub-id-type="pmid">39387960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40123-024-01042-6</pub-id><pub-id pub-id-type="pmcid">PMC11564720</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiaojuan</surname><given-names>S</given-names></name><name name-style="western"><surname>Xiaodong</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhongmei</surname><given-names>F</given-names></name><name name-style="western"><surname>Hejiang</surname><given-names>Y</given-names></name></person-group><article-title>Chinese herbal medicine combined with intravitreal antivascular growth factor agents in treatment of macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis</article-title><source>J Ophthalmol</source><year>2022</year><pub-id pub-id-type="doi">10.1155/2022/4823677</pub-id><pub-id pub-id-type="pmid">39263655</pub-id><pub-id pub-id-type="pmcid">PMC11390223</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Xiaojuan S, Xiaodong L, Zhongmei F, Hejiang Y (2022) Chinese herbal medicine combined with intravitreal antivascular growth factor agents in treatment of macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis. J Ophthalmol. 10.1155/2022/4823677<pub-id pub-id-type="pmid">39263655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/4823677</pub-id><pub-id pub-id-type="pmcid">PMC11390223</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Lu</surname><given-names>P</given-names></name></person-group><article-title>Potential mechanism of platelet GPIIb/IIIa and fibrinogen on retinal vein occlusion</article-title><source>Curr Eye Res</source><year>2024</year><volume>49</volume><issue>7</issue><fpage>731</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">38482878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02713683.2024.2327055</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ren H, Sun Y, Li Y, Yuan X, Jiang B, Zhang W, Liu G, Lu P (2024) Potential mechanism of platelet GPIIb/IIIa and fibrinogen on retinal vein occlusion. Curr Eye Res 49(7):731&#8211;741<pub-id pub-id-type="pmid">38482878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02713683.2024.2327055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Bohm EW, Buonfiglio F, Korb CA, Dauth A, Pfeiffer N, Breborowicz A, Gericke A (2024) Potential of sulodexide in the treatment of diabetic retinopathy and retinal vein occlusion. Thromb Haemost.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0044-1791232</pub-id><pub-id pub-id-type="pmid">39293483</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karatas</surname><given-names>G</given-names></name><name name-style="western"><surname>Cakir</surname><given-names>A</given-names></name><name name-style="western"><surname>Uzundede</surname><given-names>T</given-names></name><name name-style="western"><surname>Aday</surname><given-names>O</given-names></name><name name-style="western"><surname>Ozoguz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Karatas</surname><given-names>ME</given-names></name><name name-style="western"><surname>Kabakci</surname><given-names>AK</given-names></name></person-group><article-title>Dexamethasone intravitreal implant monotherapy in naive patients with macular edema secondary to retinal vein occlusion: long term follow-up retrospective cohort study</article-title><source>Int J Ophthalmol</source><year>2025</year><volume>18</volume><issue>5</issue><fpage>876</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">40385126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18240/ijo.2025.05.13</pub-id><pub-id pub-id-type="pmcid">PMC12043306</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Karatas G, Cakir A, Uzundede T, Aday O, Ozoguz AM, Karatas ME, Kabakci AK (2025) Dexamethasone intravitreal implant monotherapy in naive patients with macular edema secondary to retinal vein occlusion: long term follow-up retrospective cohort study. Int J Ophthalmol 18(5):876&#8211;882<pub-id pub-id-type="pmid">40385126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18240/ijo.2025.05.13</pub-id><pub-id pub-id-type="pmcid">PMC12043306</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mir</surname><given-names>TA</given-names></name><name name-style="western"><surname>Kherani</surname><given-names>S</given-names></name><name name-style="western"><surname>Hafiz</surname><given-names>G</given-names></name><name name-style="western"><surname>Scott</surname><given-names>AW</given-names></name><name name-style="western"><surname>Zimmer-Galler</surname><given-names>I</given-names></name><name name-style="western"><surname>Wenick</surname><given-names>AS</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>S</given-names></name><name name-style="western"><surname>Han</surname><given-names>I</given-names></name><name name-style="western"><surname>Poon</surname><given-names>D</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><etal/></person-group><article-title>Changes in retinal Nonperfusion associated with suppression of vascular endothelial growth factor in retinal vein occlusion</article-title><source>Ophthalmology</source><year>2016</year><volume>123</volume><issue>3</issue><fpage>625</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">26712560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2015.10.030</pub-id><pub-id pub-id-type="pmcid">PMC5482175</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Mir TA, Kherani S, Hafiz G, Scott AW, Zimmer-Galler I, Wenick AS, Solomon S, Han I, Poon D, He L et al (2016) Changes in retinal Nonperfusion associated with suppression of vascular endothelial growth factor in retinal vein occlusion. Ophthalmology 123(3):625&#8211;634<pub-id pub-id-type="pmid">26712560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2015.10.030</pub-id><pub-id pub-id-type="pmcid">PMC5482175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osaka</surname><given-names>R</given-names></name><name name-style="western"><surname>Muraoka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakano</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takasago</surname><given-names>Y</given-names></name><name name-style="western"><surname>Koyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Miyoshi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tsujikawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Suzuma</surname><given-names>K</given-names></name></person-group><article-title>One-year results of anti-vascular endothelial growth factor therapy combined with triamcinolone acetonide for macular edema associated with branch retinal vein occlusion</article-title><source>Jpn J Ophthalmol</source><year>2020</year><volume>64</volume><issue>6</issue><fpage>605</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">32856208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10384-020-00765-w</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Osaka R, Muraoka Y, Nakano Y, Takasago Y, Koyama Y, Miyoshi Y, Tsujikawa A, Suzuma K (2020) One-year results of anti-vascular endothelial growth factor therapy combined with triamcinolone acetonide for macular edema associated with branch retinal vein occlusion. Jpn J Ophthalmol 64(6):605&#8211;612<pub-id pub-id-type="pmid">32856208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10384-020-00765-w</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>